莫西沙星与左氧氟沙星治疗广泛耐药结核的疗效是否相当?
该研究在BALB/c小鼠模型中比较左氧氟沙星与莫西沙星对敏感及不同氟喹诺酮耐药水平结核分枝杆菌的体内活性。结果显示所有突变均降低氟喹诺酮活性,高剂量左氧氟沙星对耐药及敏感菌株的疗效均低于高剂量莫西沙星。
要点
- 所有氟喹诺酮耐药突变均降低药物活性,包括表型敏感菌株。
- 高剂量左氧氟沙星对敏感及耐药结核菌的疗效均低于高剂量莫西沙星。
- 莫西沙星对GyrA A90V突变菌仅在高剂量下表现抑菌活性。
核心结论
- 高剂量左氧氟沙星在小鼠中对氟喹诺酮敏感和耐药结核分枝杆菌的疗效均低于高剂量莫西沙星。
研究设计与样本
- BALB/c小鼠静脉感染10^6 CFU结核分枝杆菌H37Rv及三种同源突变株(GyrA A90V、GyrB E540A、GyrB A543V)。
- 左氧氟沙星50或100 mg/kg、莫西沙星60或66 mg/kg口服,每6小时一次,疗程4周。
主要发现
- 莫西沙星60和66 mg/kg q6h对H37Rv(MIC≤0.25 mg/L)、GyrB E540A和GyrB A543V(MIC=0.5 mg/L)均有杀菌活性。
- 莫西沙星60 mg/kg q6h对GyrA A90V(MIC=2 mg/L)不能阻止细菌生长,66 mg/kg q6h仅具抑菌活性。
- 左氧氟沙星50 mg/kg q6h对H37Rv(MIC≤0.25 mg/L)有杀菌活性,但对突变株无杀菌活性。
- 左氧氟沙星100 mg/kg q6h对H37Rv、GyrB E540A(MIC=0.5 mg/L)和GyrB A543V(MIC=1 mg/L)有杀菌活性,但对GyrA A90V(MIC=4 mg/L)无杀菌活性。
关键数值与推荐
- 小鼠左氧氟沙星50和100 mg/kg q6h的AUC分别相当于人左氧氟沙星750和1000 mg/day。
- 小鼠莫西沙星60和66 mg/kg q6h的AUC分别相当于人莫西沙星400和800 mg/day。
临床怎么用
- 在治疗氟喹诺酮敏感或耐药结核分枝杆菌感染时,高剂量莫西沙星可能优于高剂量左氧氟沙星。
- 表型药敏试验判为敏感的菌株仍可能因氟喹诺酮耐药突变而降低药物活性,需结合基因型评估。
局限性
- 研究为小鼠模型,结果外推至人类需谨慎。
- 仅测试了三种特定氟喹诺酮耐药突变,未涵盖其他突变类型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Moxifloxacin retains partial activity against some fluoroquinolone-resistant mutants of Mycobacterium tuberculosis . Levofloxacin is presumed to be as active as moxifloxacin against drug-susceptible tuberculosis and to have a better safety profile. OBJECTIVES: To compare the in vivo activity of levofloxacin and moxifloxacin against M. tuberculosis strains with various levels of fluoroquinolone resistance. METHODS: BALB/c mice were intravenously infected with 10 6 M. tuberculosis H37Rv and three isogenic mutants: GyrA A90V, GyrB E540A and GyrB A543V. Treatment with 50 or 100 mg/kg levofloxacin and 60 or 66 mg/kg moxifloxacin was given orally every 6 h, for 4 weeks. RESULTS: Levofloxacin 50 and 100 mg/kg q6h and moxifloxacin 60 and 66 mg/kg q6h generated AUCs in mice equivalent to those of levofloxacin 750 and 1000 mg/day and moxifloxacin 400 and 800 mg/day, respectively, in humans. Moxifloxacin 60 and 66 mg/kg q6h had bactericidal activity against strain H37Rv (MIC ≤ 0.25 mg/L) and mutants GyrB E540A and GyrB A543V (MIC = 0.5 mg/L). Against mutant GyrA A90V (MIC = 2 mg/L), moxifloxacin 60 mg/kg q6h did not prevent bacillary growth, whereas 66 mg/kg q6h had bacteriostatic activity. Levofloxacin 50 mg/kg q6h had bactericidal activity against H37Rv (MIC ≤ 0.25 mg/L) but not against the mutant strains. Levofloxacin 100 mg/kg q6h had bactericidal activity against H37Rv and mutants GyrB E540A (MIC = 0.5 mg/L) and GyrB A543V (MIC= 1 mg/L) but not against mutant GyrA A90V (MIC = 4 mg/L). CONCLUSIONS: All mutations reduced fluoroquinolone activity, even those classified as susceptible according to phenotypic tests. High-dose levofloxacin is less effective than high-dose moxifloxacin against both fluoroquinolone-resistant and -susceptible M. tuberculosis strains in mice.
引用
- Maitre T, Petitjean G, Chauffour A, et al. Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis? J Antimicrob Chemother. 2017. PMID: 28535203. doi:10.1093/jac/dkx150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。